Promoting BioTech Sciences

The health care industry in the United States is all embroiled in issues involving cost cutting and improving patient outcomes.  There is no agreement on how or whether there should be universal health care.  Health care has become a political issue, one where politicians want to have control.  Policiticians want to control the health issues of women, of people in their final stage of life, and appear to be limiting access to health care by the young, by blacks and by Hispanics who cannot afford health insurance. Health care costs are a growing part of the gross domestic product.  Errors in hospitals are a significant concern.

Yet we have some of the best doctors, nurses, drugs, and medical devices in the world.  The issue is not the individual segments of our health care system. The issue is how how health care systems work together in the United States.

One area in many of our hospitals, particularly our research hospitals is the platform they provide for clinical trials and for the creation of biotech companies and patents on promising biotech science, leading to new drugs, new devices, and new therapies.  Our hospitals, whether a research hospital or an acute care hospital, can work with entrepreneurs who have patents that can bring new therapies to patients.  Insitutional review boards (IRBs) are in place in every hospital to protect patients and encourage testing of new products, treatments and therapies.